Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Wunderlich

Showing results (51-60 of 112) with videos related to

Pageof 12
Sort By:
Blood Advances|August 31, 2022
Rational polypharmacological targeting of FLT3, JAK2, ABL, and ERK1 suppresses the adaptive resistance to FLT3 inhibitors in AMLMohammad Azhar, Zachary Kincaid, Meenu Kesarwani, et al.
Blood|June 12, 2012
Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1Jing Fang, Garrett Rhyasen, Lyndsey Bolanos, et al.
Cancer Cell|May 19, 2010
Accelerated leukemogenesis by truncated CBF beta-SMMHC defective in high-affinity binding with RUNX1Yasuhiko Kamikubo, Ling Zhao, Mark Wunderlich, et al.
Research Square|June 5, 2025
Identifying Targeted Therapies for CBFA2T3::GLIS2 Acute Myeloid LeukemiaFanny Gonzales, Constanze Schneider, Gabriela Alexe, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 12, 2015
Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemiaHelena Ågerstam, Christine Karlsson, Nils Hansen, et al.
The Journal of Clinical Investigation|May 15, 2025
Ubiquitin-conjugating enzyme UBE2N modulates proteostasis in immunoproteasome-positive acute myeloid leukemiaChiharu Ishikawa, Laura Barreyro, Avery M Sampson, et al.
Nature Communications|October 27, 2019
Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemiaYasutaka Hayashi, Susumu Goyama, XiaoXiao Liu, et al.
The Journal of Clinical Investigation|August 28, 2013
Transcription factor RUNX1 promotes survival of acute myeloid leukemia cellsSusumu Goyama, Janet Schibler, Lea Cunningham, et al.
Leukemia|October 29, 2021
Inhibition of the RacGEF VAV3 by the small molecule IODVA1 impedes RAC signaling and overcomes resistance to tyrosine kinase inhibition in acute lymphoblastic leukemiaShailaja Hegde, Anjelika Gasilina, Mark Wunderlich, et al.
Leukemia|January 8, 2026
Identifying targeted therapies for CBFA2T3::GLIS2 acute myeloid leukemiaFanny Gonzales, Constanze Schneider, Gabriela Alexe, et al.
Pageof 12

Showing results (51-60 of 112) with videos related to

Sort By:
Pageof 12
Blood Advances|August 31, 2022
Rational polypharmacological targeting of FLT3, JAK2, ABL, and ERK1 suppresses the adaptive resistance to FLT3 inhibitors in AMLMohammad Azhar, Zachary Kincaid, Meenu Kesarwani, et al.
Blood|June 12, 2012
Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1Jing Fang, Garrett Rhyasen, Lyndsey Bolanos, et al.
Cancer Cell|May 19, 2010
Accelerated leukemogenesis by truncated CBF beta-SMMHC defective in high-affinity binding with RUNX1Yasuhiko Kamikubo, Ling Zhao, Mark Wunderlich, et al.
Research Square|June 5, 2025
Identifying Targeted Therapies for CBFA2T3::GLIS2 Acute Myeloid LeukemiaFanny Gonzales, Constanze Schneider, Gabriela Alexe, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 12, 2015
Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemiaHelena Ågerstam, Christine Karlsson, Nils Hansen, et al.
The Journal of Clinical Investigation|May 15, 2025
Ubiquitin-conjugating enzyme UBE2N modulates proteostasis in immunoproteasome-positive acute myeloid leukemiaChiharu Ishikawa, Laura Barreyro, Avery M Sampson, et al.
Nature Communications|October 27, 2019
Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemiaYasutaka Hayashi, Susumu Goyama, XiaoXiao Liu, et al.
The Journal of Clinical Investigation|August 28, 2013
Transcription factor RUNX1 promotes survival of acute myeloid leukemia cellsSusumu Goyama, Janet Schibler, Lea Cunningham, et al.
Leukemia|October 29, 2021
Inhibition of the RacGEF VAV3 by the small molecule IODVA1 impedes RAC signaling and overcomes resistance to tyrosine kinase inhibition in acute lymphoblastic leukemiaShailaja Hegde, Anjelika Gasilina, Mark Wunderlich, et al.
Leukemia|January 8, 2026
Identifying targeted therapies for CBFA2T3::GLIS2 acute myeloid leukemiaFanny Gonzales, Constanze Schneider, Gabriela Alexe, et al.
Pageof 12